KONSTANTINOS TRIPODIS: Open Payments
NPI 1588698534 · BURBANK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$241,808 in 203 payments from 7 companies in 2025. Trend: 2023 $147,395 · 2024 $192,054 · 2025 $241,808
Speaker / faculty: $207,584Consulting: $16,640Travel & lodging: $10,624Food & beverage: $6,960
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 62 | $84,824 |
| Neurocrine BioSciences, Inc. | 54 | $67,322 |
| Otsuka America Pharmaceutical, Inc. | 29 | $42,479 |
| Alkermes, Inc. | 25 | $24,495 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $22,439 |
| E.R. Squibb & Sons, L.L.C. | 4 | $222 |
| Lundbeck LLC | 1 | $25 |
Products named: UZEDY, INGREZZA, ABILIFY MAINTENA, LYBALVI, CAPLYTA, COBENFY, ARISTADA, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
